Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses

Stroke

Volumn 45, Issue 8, 2014, Pages 2354-2358

  Wang, Yongjun ^a   Liao, Xiaoling ^a   Wang, Yilong ^a   Pan, Yuesong ^a   Wang, Chunjuan ^a   Zhao, Xingquan ^a   Wang, David Z ^a   Wang, Chunxue ^a   Liu, Liping ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

safety; stroke; thrombolytic therapy

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; ASIAN; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANKIN SCALE; RISK BENEFIT ANALYSIS; SYMPTOM; TREATMENT OUTCOME;

SAFETY; STROKE; THROMBOLYTIC THERAPY;

AGED; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84905372293     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005989     Document Type: Article

References (21)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
4. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992;23:641-645.
5. Dharmasaroja PA, Pattaraarchachai J. Low vs standard dose of recombinant tissue plasminogen activator in treating East Asian patients with acute ischemic stroke. Neurol India. 2011;59:180-184.
6. Loh PK, Sharma VK. Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in acute ischemic stroke. Stroke. 2010;41:e164, author reply 165.
7. Chen CH, Hsieh CY, Lai TB, Chuang MT, Chen WL, Sun MC. Optimal dose for stroke thrombolysis in Asians: low dose may have similar safety and efficacy as standard dose. J Thromb Haemost. 2012;10:1270-1275.
8. Sharma VK, Ng KW, Venketasubramanian N, Saqqur M, Teoh HL, Kaul S, et al. Current status of intravenous thrombolysis for acute ischemic stroke in Asia. Int J Stroke. 2011;6:523-530.
9. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al; J-MARS Investigators. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke. 2010;41:1984-1989.
10. Liao XL, Wang CX, Wang YL, Wang CJ, Zhao XQ, Zhang LQ, et al; Thrombolysis Implementation and Monitor of acute ischemic Stroke in China (TIMS-China) Investigators. Implementation and outcome of thrombolysis with alteplase 3 to 4.5 h after acute stroke in Chinese patients. CNS Neurosci Ther. 2013;19:43-47.
11. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke- Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282.
12. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
13. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
14. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
15. Ueshima S, Matsuo O. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb Haemost. 2002;87:544-546.
16. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/ kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37:1810-1815.
17. Zhou XY, Wang SS, Collins ML, Davis SM, Yan B. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. J Clin Neurosci. 2010;17:988-992.
18. Chao AC, Hsu HY, Chung CP, Liu CH, Chen CH, Teng MM, et al; Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study Group. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke. 2010;41:885-890.
19. Sharma VK, Tsivgoulis G, Tan JH, Wong LY, Ong BK, Chan BP, et al. Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore. J Stroke Cerebrovasc Dis. 2010;19:424-430.
20. Nguyen TH, Truong AL, Ngo MB, Bui CT, Dinh QV, Doan TC, et al. Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam Thrombolysis Registry. Eur J Neurol. 2010;17:1188-1192.
21. Ahmad A, Sharma VK. More on: optimal dose for stroke thrombolysis in Asians. J Thromb Haemost. 2012;10:1970-1971.